Want to see KR:293480 full AI Analyst Report?
Top Page
Hana Pharm Co., Ltd.
(293480)
Select Model
Select Model
Rating:60Neutral
Price Target:
₩8,579.00
Action:N/A
Date:10/28/26
The score is anchored by strong top-line growth and healthy gross/operating margins, supported by attractive valuation (low P/E and meaningful dividend yield). These positives are offset by significant cash-flow pressure (weak cash conversion and deeply negative free cash flow) and a clearly weak technical setup with price below major moving averages and negative momentum indicators.
Positive Factors
Strong Revenue Growth
The sharp TTM revenue increase indicates substantial expansion in the company’s pharmaceutical sales base and commercial reach. If the growth is sustained, it can provide operating leverage, support reinvestment in drug development and commercialization, and strengthen Hana Pharm’s position in its target markets over the coming quarters.
Negative Factors
Deeply Negative Free Cash Flow
Persistent negative free cash flow means reported profitability is not currently translating into cash available for debt reduction, dividends, or discretionary investment. If the shortfall continues, Hana Pharm may need additional financing or must moderate expansion spending, increasing execution and funding risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The sharp TTM revenue increase indicates substantial expansion in the company’s pharmaceutical sales base and commercial reach. If the growth is sustained, it can provide operating leverage, support reinvestment in drug development and commercialization, and strengthen Hana Pharm’s position in its target markets over the coming quarters.
Read all positive factors
Hana Pharm Co., Ltd. (293480) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩141.34B
Dividend Yield3.18%
Average Volume (3M)15.11K
Price to Earnings (P/E)8.3
Beta (1Y)0.08
Revenue Growth7.46%
EPS Growth-14.42%
CountryKR
Employees730
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)982.93
Shares Outstanding17,772,945
10 Day Avg. Volume18,984
30 Day Avg. Volume15,108
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)0.64
Price to Sales (P/S)0.83
P/FCF Ratio-10.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1,247
Revenue Forecast (FY)₩257.30B
Hana Pharm Co., Ltd. Business Overview & Revenue Model
Company Description
Hana Pharm Co., Ltd. is a pharmaceutical enterprise that manufactures and supplies a diverse range of medicinal goods to both domestic South Korean and international markets. Its comprehensive product line covers various therapeutic categories, su...
Hana Pharm Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 247.31B | 239.50B | 225.34B | 224.46B | 210.84B | 196.41B |
| Gross Profit | 151.99B | 146.39B | 141.29B | 139.58B | 131.24B | 130.82B |
| EBITDA | 41.60B | 36.95B | 32.87B | 34.68B | 37.80B | 41.65B |
| Net Income | 17.46B | 8.78B | 21.25B | 22.33B | 24.31B | 28.01B |
Balance Sheet | ||||||
| Total Assets | 446.69B | 418.14B | 382.01B | 348.39B | 345.96B | 303.50B |
| Cash, Cash Equivalents and Short-Term Investments | 17.28B | 13.47B | 12.16B | 6.16B | 17.58B | 56.87B |
| Total Debt | 68.84B | 58.72B | 29.13B | 26.53B | 34.10B | 10.77B |
| Total Liabilities | 114.94B | 104.73B | 72.83B | 70.40B | 77.57B | 51.60B |
| Stockholders Equity | 331.75B | 313.41B | 309.18B | 277.98B | 268.40B | 251.90B |
Cash Flow | ||||||
| Free Cash Flow | -52.99B | -19.87B | 12.09B | 3.72B | -4.89B | -9.16B |
| Operating Cash Flow | 16.43B | 9.18B | 25.30B | 18.40B | 30.88B | 25.66B |
| Investing Cash Flow | -36.99B | -29.98B | -11.62B | -11.89B | -36.51B | -35.50B |
| Financing Cash Flow | 32.03B | 22.13B | -6.81B | -17.64B | 11.56B | -4.09B |
Hana Pharm Co., Ltd. Technical Analysis
Negative
―
Price Trends
8381.40
Negative
8568.60
Negative
9238.25
Negative
Market Momentum
-45.86
Positive
39.54
Neutral
29.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:293480, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 8313.50, equal to the 50-day MA of 8381.40, and equal to the 200-day MA of 9238.25, indicating a bearish trend. The MACD of -45.86 indicates Positive momentum. The RSI at 39.54 is Neutral, neither overbought nor oversold. The STOCH value of 29.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:293480.
Hana Pharm Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₩141.34B | 8.31 | ― | 3.18% | 7.46% | -14.42% | |
58 Neutral | ₩144.41B | 7.86 | ― | 4.70% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₩128.67B | 7.32 | ― | 0.30% | -17.85% | 81.91% | |
50 Neutral | ₩169.19B | 63.80 | ― | 3.22% | 1.83% | -67.89% | |
47 Neutral | ₩167.66B | -4.41 | ― | 0.96% | -4.54% | -88.02% | |
44 Neutral | ₩117.74B | -0.85 | ― | ― | -2.43% | -234.71% |
* General Sector Average
KR:293480
Hana Pharm Co., Ltd.
8,170.00
-3,311.32
-28.84%
KR:000020
Dong Wha Pharm Co., Ltd.
5,210.00
-990.45
-15.97%
KR:000520
Samil Pharmaceutical Co., Ltd.
7,780.00
-1,690.00
-17.85%
KR:001360
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
1,251.00
-242.00
-16.21%
KR:003220
Daewon Pharmaceutical Co., Ltd
7,760.00
-5,120.31
-39.75%
KR:271980
Jeil Pharmaceutical Co. Ltd.
8,830.00
-5,760.00
-39.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.